Entrada's Duchenne drug shown to improve muscle function in early trial

Entrada Therapeutics said its drug improved a key measure of muscle function in children with Duchenne muscular dystrophy in an early-to-mid stage trial. The readout is a positive clinical update for a rare, fatal muscle-wasting disease, though the study is still early and no statistical details were provided. The news is supportive for the company’s pipeline but is unlikely to be a broad market mover.

Analysis

Entrada Therapeutics said its drug improved a key measure of muscle function in children with Duchenne muscular dystrophy in an early-to-mid stage trial. The readout is a positive clinical update for a rare, fatal muscle-wasting disease, though the study is still early and no statistical details were provided. The news is supportive for the company’s pipeline but is unlikely to be a broad market mover.